Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Retained Earnings (2016 - 2025)

Lineage Cell Therapeutics' Retained Earnings history spans 16 years, with the latest figure at -$3.9 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 36.3% year-over-year to -$3.9 million; the TTM value through Dec 2025 reached -$3.9 million, down 36.3%, while the annual FY2025 figure was -$3.9 million, 36.3% down from the prior year.
  • Retained Earnings reached -$3.9 million in Q4 2025 per LCTX's latest filing, up from -$4.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$2.1 million in Q1 2021 to a low of -$438.1 million in Q2 2025.
  • Average Retained Earnings over 5 years is -$206.6 million, with a median of -$318.7 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: soared 99.34% in 2024, then crashed 17635.55% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$337.1 million in 2021, then dropped by 7.79% to -$363.4 million in 2022, then surged by 99.16% to -$3.1 million in 2023, then rose by 6.26% to -$2.9 million in 2024, then plummeted by 36.3% to -$3.9 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Retained Earnings are -$3.9 million (Q4 2025), -$4.3 million (Q3 2025), and -$438.1 million (Q2 2025).